Literature DB >> 6420562

HLA-DR antigens and proteinuria induced by aurothioglucose and D-penicillamine in patients with rheumatoid arthritis.

F Speerstra, P Reekers, L B van de Putte, J P Vandenbroucke, J J Rasker, D J de Rooij.   

Abstract

By means of a case-control study we investigated the association between HLA phenotypes and the development of proteinuria after aurothioglucose or D-penicillamine treatment in patients with rheumatoid arthritis (RA). HLA-DR3 was markedly increased in 44 treatment cases compared with 66 RA controls (46 versus 18%, p = 0.002). HLA-DR3 positive patients were at greater risk during treatment with D-penicillamine (RR 10.1, p = 0.001) than gold treated cases (RR 1.7, p = 0.365). The associations between HLA-DR3 and nephrotic syndrome (RR = 6.3, p = 0.004) and early onset proteinuria (RR = 5.4, p less than 0.001) were stronger compared with uncomplicated proteinuria (RR = 3.1, p = 0.017) and late-onset proteinuria (RR = 1.6, p = 0.459), respectively. It appears that genetic factors in RA influence the development, the degree and the time of onset of drug induced proteinuria.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6420562

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  10 in total

Review 1.  Human leukocyte antigen polymorphisms and personalized medicine for rheumatoid arthritis.

Authors:  Hiroshi Furukawa; Shomi Oka; Kota Shimada; Atsushi Hashimoto; Shigeto Tohma
Journal:  J Hum Genet       Date:  2015-04-23       Impact factor: 3.172

Review 2.  Adverse reactions with oral and parenteral gold preparations.

Authors:  E C Tozman; N L Gottlieb
Journal:  Med Toxicol       Date:  1987 May-Jun

3.  Chrysotherapy and thrombocytopenia.

Authors:  R Madhok; T Pullar; H A Capell; F Dawood; R D Sturrock; H M Dick
Journal:  Ann Rheum Dis       Date:  1985-09       Impact factor: 19.103

4.  Epidemiological study of HLA and GM in rheumatoid arthritis and related symptoms in an open Dutch population.

Authors:  B M de Jongh; L K van Romunde; H A Valkenburg; G G de Lange; J J van Rood
Journal:  Ann Rheum Dis       Date:  1984-08       Impact factor: 19.103

5.  Methotrexate in refractory rheumatoid arthritis.

Authors:  A M Boerbooms; M E Jeurissen; A A Westgeest; H Theunisse; L B Van de Putte
Journal:  Clin Rheumatol       Date:  1988-06       Impact factor: 2.980

6.  HLA antigens and seronegative rheumatoid arthritis.

Authors:  T Bardin; L Legrand; B Naveau; A Marcelli-Barge; N Debeyre; G M Lathrop; J C Poirier; M Schmid; A Ryckewaert; A Dryll
Journal:  Ann Rheum Dis       Date:  1985-01       Impact factor: 19.103

7.  HLA antigens and toxic reactions to sodium aurothiopropanol sulphonate and D-penicillamine in patients with rheumatoid arthritis.

Authors:  P Perrier; C Raffoux; P Thomas; J N Tamisier; M Busson; A Gaucher; F Streiff
Journal:  Ann Rheum Dis       Date:  1985-09       Impact factor: 19.103

8.  HLA antigens and adverse drug reactions to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis.

Authors:  S R Dahlqvist; H Ström; A Bjelle; E Möller
Journal:  Clin Rheumatol       Date:  1985-03       Impact factor: 2.980

Review 9.  Genetics of Interstitial Lung Disease: Vol de Nuit (Night Flight).

Authors:  Hiroshi Furukawa; Shomi Oka; Kota Shimada; Naoyuki Tsuchiya; Shigeto Tohma
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-04-29

10.  HLA-DRB1*08:02 Is Associated with Bucillamine-Induced Proteinuria in Japanese Rheumatoid Arthritis Patients.

Authors:  Hiroshi Furukawa; Shomi Oka; Kota Shimada; Shoji Sugii; Atsushi Hashimoto; Akiko Komiya; Naoshi Fukui; Taiichiro Miyashita; Kiyoshi Migita; Akiko Suda; Shouhei Nagaoka; Naoyuki Tsuchiya; Shigeto Tohma
Journal:  Biomark Insights       Date:  2014-05-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.